DaTscan: (I-123 Ioflupane)

INDICATIONS:
- Indicated for striatal dopamine transporter visualization using SPECT imaging for the evaluation of adult patients with suspected Parkinsonian syndromes.

CONTRAINDICATIONS:
- Known hypersensitivity to the active substance or to any of its excipients. An iodine allergy is not a contraindication to receiving the tracer.
- Inability to cooperate with SPECT or SPECT/CT brain imaging.
- Pregnancy.

ADVERSE REACTIONS:
- In clinical trials the most common adverse reactions; headache, nausea, vertigo, dry mouth and dizziness occurred in < 1% of subjects.
- Injection site reactions.

SUPPLIED AND STORAGE:
- Supplied in 10 ml glass vials containing a total volume of 2.5 ml of solution with a total radioactivity of 185 MBq (5 mCi) at calibration time.
- Store DaTscan at 200 to 250 °C (680 to 770), within the original lead container or equivalent.
- Does not contain a preservative.
- Do not use DaTscan preparations after the expiration date and time stated on label.

PATIENT PREPARATION:
- Check medications that may alter tracer binding, and (if possible) stop such medications for at least 5 half-lives.
- To reduce exposure to the thyroid, administer a single 400 mg dose of potassium perchlorate or a single dose of Lugol’s solution (equivalent to 100 mg of iodine) at least 1 hour prior to injection.
- Avoid the use of these products in patients with known sensitivities.

DOSE AND ADMINISTRATION:
- 111 to 185 MBq (3 to 5 mCi) administered intravenously.
- Inspect the radiopharmaceutical dose solution prior to administration and do not use it if it contains particulate material or is discolored.

IMAGING PARAMETERS:
- SPECT imaging should be started between 3 and 6 hours after injection.
- Keep the patient supine with the head positioned to center the brain in the scanner field of view.
- Reduce head movement with tape or other flexible head restraints if necessary.

PATIENT INSTRUCTION:
- Advise patient to hydrate and void after procedure for 48 hours after tracer administration to reduce radiation exposure if possible.
- Inform patients who are breastfeeding to use alternate infant nutrition sources (e.g. stored breast milk or infant formula) for 6 days after administration of the drug.